CN110075239A - Nanoemulsions and its preparation method and application - Google Patents
Nanoemulsions and its preparation method and application Download PDFInfo
- Publication number
- CN110075239A CN110075239A CN201910452475.7A CN201910452475A CN110075239A CN 110075239 A CN110075239 A CN 110075239A CN 201910452475 A CN201910452475 A CN 201910452475A CN 110075239 A CN110075239 A CN 110075239A
- Authority
- CN
- China
- Prior art keywords
- oil
- nanoemulsion
- mixture
- preparation
- primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000003921 oil Substances 0.000 claims abstract description 54
- 239000009718 asarum oil Substances 0.000 claims abstract description 31
- 239000010671 sandalwood oil Substances 0.000 claims abstract description 31
- 239000010646 galangal oil Substances 0.000 claims abstract description 30
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 25
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 19
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940116229 borneol Drugs 0.000 claims abstract description 19
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 19
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000002245 particle Substances 0.000 claims abstract description 19
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 15
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 208000032382 Ischaemic stroke Diseases 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 127
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000012071 phase Substances 0.000 claims description 25
- 239000008346 aqueous phase Substances 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 230000003204 osmotic effect Effects 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 7
- 235000019510 Long pepper Nutrition 0.000 claims description 6
- 240000003455 Piper longum Species 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 4
- 229940114069 12-hydroxystearate Drugs 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 8
- 238000009827 uniform distribution Methods 0.000 abstract description 5
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 239000007922 nasal spray Substances 0.000 abstract description 3
- 238000011065 in-situ storage Methods 0.000 abstract description 2
- 210000003928 nasal cavity Anatomy 0.000 abstract description 2
- 229940100652 nasal gel Drugs 0.000 abstract description 2
- 229940097496 nasal spray Drugs 0.000 abstract description 2
- 125000005313 fatty acid group Chemical group 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 12
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 8
- 229940069338 potassium sorbate Drugs 0.000 description 8
- 235000010241 potassium sorbate Nutrition 0.000 description 8
- 239000004302 potassium sorbate Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 241001481710 Cerambycidae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001256 steam distillation Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 240000001606 Adenanthera pavonina Species 0.000 description 1
- 235000011470 Adenanthera pavonina Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种纳米乳液及其制备方法和用途。以檀香油、高良姜油、细辛油、荜茇油和冰片为活性成分,以脂肪酸修饰的聚乙二醇为乳化剂,制备得到纳米乳液。本发明的方法所得纳米乳液的平均粒径小,且分布均匀。本发明将纳米乳液制成鼻用喷雾剂或者加入原位凝胶制成鼻用凝胶剂,通过鼻腔给药,用于治疗缺血型脑卒中。
The invention discloses a nanoemulsion, its preparation method and application. The nanoemulsion was prepared with sandalwood oil, galangal oil, asarum oil, longan oil and borneol as active ingredients, and polyethylene glycol modified with fatty acid as emulsifier. The nanoemulsion obtained by the method of the invention has a small average particle size and uniform distribution. In the present invention, the nanoemulsion is made into a nasal spray or an in-situ gel is added into a nasal gel, which is administered through the nasal cavity to treat ischemic stroke.
Description
技术领域technical field
本发明涉及一种纳米乳液及其制备方法和用途。The invention relates to a nanoemulsion and its preparation method and application.
背景技术Background technique
宽胸气雾剂已载入我国国家药品标准(标准号WS3-B-2417-97),其处方组成为细辛油23ml,檀香油70ml、高良姜油32ml、荜茇油15ml和冰片22.5g。将四种挥发油混匀,加热至40℃,加入研细的冰片,微热溶解后用无水乙醇调整总量至625ml,混匀后每瓶按含挥发油2ml灌封到耐压气雾剂瓶中,压入抛射剂(二氟二氯甲烷)12g,即得。宽胸气雾剂依据“以通为补、以通为主”的“芳香温通”理论研制而成,具有辛温通阳,理气止痛的功能。用于阴寒阻滞、气机郁闭所致的胸痹,是治疗冠心病、心绞痛的速效止痛的有效方剂。Kuanxiong aerosol has been included in China's national drug standards (standard number WS 3 -B-2417-97), and its prescription is composed of asarum oil 23ml, sandalwood oil 70ml, galangal oil 32ml, longan oil 15ml and borneol 22.5ml g. Mix the four kinds of volatile oils, heat to 40°C, add finely ground borneol, dissolve with slight heat, adjust the total amount to 625ml with absolute ethanol, after mixing, fill each bottle with 2ml of volatile oil and seal it into a pressure-resistant aerosol bottle , press into the propellant (difluorodichloromethane) 12g, that is. Kuanxiong aerosol is developed according to the theory of "aroma, warming and dredging" that "takes dredging as the supplement and focuses on dredging". It is an effective prescription for quick-acting pain relief for coronary heart disease and angina pectoris.
CN1732908A公开了一种含有冰片的喷雾剂,按重量百分比计,其含有0.48~8%的冰片、0.5~8.3%的细辛油、1.5~25%的檀香油、0.7~11.5%的高良姜油、0.32~5.3%的荜茇油、0~5%的附加剂、10~30%的乙醇,余量的中链C8~C12饱和脂肪酸制备的脂肪酸甘油酯。上述喷雾剂并未形成纳米尺寸的分散液。CN1732908A discloses a spray containing borneol, which contains 0.48-8% borneol, 0.5-8.3% asarum oil, 1.5-25% sandalwood oil, and 0.7-11.5% galangal oil by weight percentage , 0.32-5.3% permium oil, 0-5% additive, 10-30% ethanol, and fatty acid glyceride prepared from medium-chain C 8 -C 12 saturated fatty acid in the balance. The aforementioned sprays do not form nano-sized dispersions.
发明内容SUMMARY OF THE INVENTION
本发明的一个目的在于提供一种纳米乳液的制备方法,可以获得平均粒径小且分布均匀的纳米乳液。进一步地,所得到的纳米乳液的稳定性好。One object of the present invention is to provide a method for preparing nanoemulsions, which can obtain nanoemulsions with small average particle size and uniform distribution. Further, the obtained nanoemulsion has good stability.
本发明的另一目的在于提供一种纳米乳液,平均粒径小且分布均匀。Another object of the present invention is to provide a nanoemulsion with small average particle size and uniform distribution.
本发明的再一目的在于提供上述纳米乳液的用途。Another object of the present invention is to provide the use of the above-mentioned nanoemulsion.
一方面,本发明提供一种纳米乳液的制备方法,包括如下步骤:以檀香油、高良姜油、细辛油、荜茇油和冰片为活性成分,以式(Ⅰ)所示的化合物为乳化剂,制备得到纳米乳液,On the one hand, the present invention provides a kind of preparation method of nanoemulsion, comprises the following steps: take sandalwood oil, galangal oil, asarum oil, Piper longum oil and borneol as active ingredient, take the compound shown in formula (I) as emulsification agent to prepare a nanoemulsion,
在式(Ⅰ)中,R为含有至少一个羟基的C6~C30烷基,PEG表示聚乙二醇链段。In formula (I), R is a C6-C30 alkyl group containing at least one hydroxyl group, and PEG represents a polyethylene glycol segment.
根据本发明的制备方法,优选地,在式(Ⅰ)中,R为含有至少一个羟基的C10~C25烷基。According to the preparation method of the present invention, preferably, in formula (I), R is a C10-C25 alkyl group containing at least one hydroxyl group.
根据本发明的制备方法,优选地,所述乳化剂为聚乙二醇-12-羟基硬脂酸酯,其结构如式(Ⅱ)所示,According to the preparation method of the present invention, preferably, the emulsifier is polyethylene glycol-12-hydroxystearate, the structure of which is shown in formula (II),
其中,PEG表示聚乙二醇链段。Wherein, PEG represents a polyethylene glycol segment.
根据本发明的制备方法,优选地,以%(w/v)计的乳化剂质量体积百分比浓度与以%(v/v)计的初级混合物体积浓度之间的比例α为0.3~1.0:1;其中,所述初级混合物由檀香油、高良姜油、细辛油和荜茇油组成。According to the preparation method of the present invention, preferably, the ratio α between the mass volume percent concentration of the emulsifier in % (w/v) and the volume concentration of the primary mixture in % (v/v) is 0.3 to 1.0:1 ; Wherein, the primary mixture is composed of sandalwood oil, galangal oil, asarum oil and longicorn oil.
根据本发明的制备方法,优选地,包括如下步骤:According to the preparation method of the present invention, preferably, comprises the following steps:
(1)将作为活性成分的檀香油、高良姜油、细辛油、荜茇油和冰片形成油相混合物;(1) Sandalwood oil, galangal oil, Asarum oil, Piper longum oil and Borneolum as active ingredient are formed into an oil phase mixture;
(2)将所述乳化剂与油相混合物混合均匀,得到第一混合物;(2) uniformly mixing the emulsifier and the oil phase mixture to obtain the first mixture;
(3)将辅料分散于水中,得到水相混合物;其中,所述辅料包括渗透压调节剂和/或防腐剂;(3) dispersing the auxiliary material in water to obtain an aqueous phase mixture; wherein, the auxiliary material includes an osmotic pressure regulator and/or a preservative;
(4)将所述水相混合物与所述第一混合物混合,得到第二混合物;(4) mixing the aqueous phase mixture with the first mixture to obtain a second mixture;
(5)将所述第二混合物升温至40~60℃,然后降温至15~25℃,得到初级纳米乳液;(5) raising the temperature of the second mixture to 40-60°C, and then cooling down to 15-25°C to obtain a primary nanoemulsion;
(6)用pH调节剂将所述初级纳米乳液的pH调节至5.5~6.5后,加水定容,得到所述纳米乳液。(6) After the pH of the primary nanoemulsion is adjusted to 5.5-6.5 with a pH regulator, water is added to constant volume to obtain the nanoemulsion.
根据本发明的制备方法,优选地,步骤(2)中,以%(w/v)计的乳化剂质量体积百分比浓度与以%(v/v)计的初级混合物体积浓度之间的比例α为0.3~1.0:1;其中,所述初级混合物由檀香油、高良姜油、细辛油和荜茇油组成。According to the preparation method of the present invention, preferably, in step (2), the ratio α between the mass volume percent concentration of the emulsifier in % (w/v) and the volume concentration of the primary mixture in % (v/v) 0.3~1.0:1; Wherein, the primary mixture is composed of sandalwood oil, galangal oil, asarum oil and longicorn oil.
根据本发明的制备方法,优选地,所述纳米乳液中,所述乳化剂的质量体积百分比浓度为1.2~15%(w/v),初级混合物的体积浓度为2~15%(v/v)。According to the preparation method of the present invention, preferably, in the nanoemulsion, the mass volume percent concentration of the emulsifier is 1.2 to 15% (w/v), and the volume concentration of the primary mixture is 2 to 15% (v/v ).
根据本发明的制备方法,优选地,檀香油、高良姜油、细辛油和荜茇油的体积比为40~65:15~30:10~25:3~20;以檀香油、高良姜油、细辛油和荜茇油的总体积为1ml计,所述冰片的用量为0.1~0.25g。According to the preparation method of the present invention, preferably, the volume ratio of sandalwood oil, galangal oil, asarum oil and longan oil is 40~65:15~30:10~25:3~20; The total volume of the oil, the asarum oil and the longan oil is 1 ml, and the amount of the borneol is 0.1-0.25 g.
另一方面,本发明提供一种纳米乳液,其通过上述制备方法得到,所述纳米乳液的平均粒径小于100nm,多分散指数PDI小于0.3。On the other hand, the present invention provides a nanoemulsion obtained by the above preparation method, the average particle diameter of the nanoemulsion is less than 100nm, and the polydispersity index PDI is less than 0.3.
再一方面,本发明还提供所述纳米乳液在制备治疗缺血型脑卒中的药物中的用途。In another aspect, the present invention also provides the use of the nanoemulsion in the preparation of a drug for treating ischemic stroke.
本发明的制备纳米乳液的方法中,采用脂肪酸修饰的聚乙二醇为乳化剂,能够制得平均粒径小且分布均匀的纳米乳液。进一步地,所得到的纳米乳液的稳定性好。In the method for preparing the nanoemulsion of the present invention, the polyethylene glycol modified by fatty acid is used as the emulsifier, so that the nanoemulsion with small average particle size and uniform distribution can be prepared. Further, the obtained nanoemulsion has good stability.
附图说明Description of drawings
图1为不同浓度的HS15下形成的纳米乳液的平均粒径和多分散指数图。Figure 1 shows different concentrations of Average particle size and polydispersity index plots of nanoemulsions formed at HS15.
图2为不同浓度的HS15下形成的纳米乳液的稳定性测试图。Figure 2 shows different concentrations of Stability test graph of nanoemulsions formed under HS15.
具体实施方式Detailed ways
下面结合具体实施例对本发明作进一步的说明,但本发明的保护范围并不限于此。The present invention will be further described below in conjunction with specific examples, but the protection scope of the present invention is not limited thereto.
在本发明中,相转变温度表示表面活性剂的亲水亲油性质达到适当平衡的温度。平均粒径表示乳液中纳米粒子的平均尺寸,通常以数均粒径表示。In the present invention, the phase transition temperature means the temperature at which the hydrophilic and lipophilic properties of the surfactant reach an appropriate balance. The average particle size represents the average size of the nanoparticles in the emulsion, usually expressed as a number average particle size.
本发明中,所述檀香油为檀香科植物檀香树干的干燥心材经水蒸气蒸馏提取的挥发油;所述高良姜油为姜科植物高良姜的根茎经水蒸气蒸馏提取的挥发油;所述细辛油为马览铃科植物北细辛、汉城细羊或华细辛的干燥根和根茎经水蒸气蒸馏提取的挥发油;所述荜茇油为胡椒科植物荜茇的干燥近成熟或成熟果穗经水蒸气蒸馏提取的挥发油。In the present invention, the sandalwood oil is the volatile oil extracted by steam distillation from the dry heartwood of the sandalwood tree trunk of the plant of the family Zingiberaceae; The oil is the volatile oil extracted by steam distillation from the dry roots and rhizomes of Asarum chinensis, Hancheng Xiyang or Huaxixin; Volatile oil extracted by steam distillation.
<纳米乳液的制备方法><Preparation method of nanoemulsion>
本发明采用相转变温度法制备纳米乳液。该工艺的能耗低,成本低。本发明的纳米乳液的制备方法包括如下步骤:以檀香油、高良姜油、细辛油、荜茇油和冰片为活性成分,以式(Ⅰ)所示的化合物为乳化剂,制备得到纳米乳液。The invention adopts the phase transition temperature method to prepare the nanoemulsion. The process has low energy consumption and low cost. The preparation method of the nanoemulsion of the present invention comprises the steps of: taking sandalwood oil, galangal oil, asarum oil, longan oil and borneol as active ingredients, and using the compound shown in formula (I) as an emulsifier to prepare the nanoemulsion .
在式(Ⅰ)中,R为含有至少一个羟基的C6~C30烷基;PEG表示聚乙二醇链段。该烷基可以为直链烷基或者带有支链的烷基。本发明意外地发现,采用上述结构的乳化剂与宽胸气雾剂的组分配合,可以得到平均粒径小且分布均匀的纳米乳液。In formula (I), R is a C6-C30 alkyl group containing at least one hydroxyl group; PEG represents a polyethylene glycol segment. The alkyl group may be straight-chain or branched. The present invention unexpectedly finds that the nanoemulsion with small average particle size and uniform distribution can be obtained by combining the emulsifier with the above-mentioned structure with the components of the broad chest aerosol.
在式(Ⅰ)中,取代基R可以为含有至少一个羟基的C6~C30烷基,优选为含有至少一个羟基的C10~C25烷基,还优选为含有至少一个羟基的C13~C20烷基,更优选为含有至少一个羟基的C16~C19烷基。R的羟基数量为至少一个,优选为1~2个。在某些实施方案中,R含有两个羟基。两个羟基可以位于不同的碳原子上,也可以位于同一个碳原子上。在另一些实施方案中,R仅含有一个羟基。取代基R的具体的实例包括但不限于12-羟基十八烷基或者15-羟基十八烷基。PEG的聚合度并没有特别限定,例如为5~200,优选为10~100。根据本发明的一个优选实施方式,乳化剂为如式(Ⅱ)所示的聚乙二醇-12-羟基硬脂酸酯,其具有如下结构式:In formula (I), the substituent R may be a C6-C30 alkyl group containing at least one hydroxyl group, preferably a C10-C25 alkyl group containing at least one hydroxyl group, and preferably a C13-C20 alkyl group containing at least one hydroxyl group, More preferably, it is a C16-C19 alkyl group containing at least one hydroxyl group. The number of hydroxyl groups in R is at least one, preferably 1-2. In certain embodiments, R contains two hydroxyl groups. The two hydroxyl groups can be located on different carbon atoms or on the same carbon atom. In other embodiments, R contains only one hydroxyl group. Specific examples of substituent R include, but are not limited to, 12-hydroxyoctadecyl or 15-hydroxyoctadecyl. The degree of polymerization of PEG is not particularly limited, and is, for example, 5-200, preferably 10-100. According to a preferred embodiment of the present invention, the emulsifier is polyethylene glycol-12-hydroxystearate as shown in formula (II), which has the following structural formula:
在式(II)中,PEG表示聚乙二醇链段。采用上述乳化剂可以增强纳米乳液稳定性。In formula (II), PEG represents a polyethylene glycol segment. Using the emulsifier mentioned above can enhance the stability of the nanoemulsion.
根据本发明的一个实施方式,以%(w/v)计的乳化剂质量体积百分比浓度与以%(v/v)计的初级混合物体积浓度之间的比例α为0.3~1.0:1;其中,所述初级混合物由檀香油、高良姜油、细辛油和荜茇油组成。α优选为0.35~0.8:1,还优选为0.4~0.7,更优选为0.5~0.6:1。这样有助于进一步获得稳定性好的纳米乳液。According to one embodiment of the present invention, the ratio α between the mass volume percent concentration of the emulsifier in % (w/v) and the volume concentration of the primary mixture in % (v/v) is 0.3 to 1.0:1; wherein , the primary mixture is composed of sandalwood oil, galangal oil, asarum oil and longan oil. α is preferably 0.35 to 0.8:1, further preferably 0.4 to 0.7, more preferably 0.5 to 0.6:1. This helps to further obtain a stable nanoemulsion.
根据本发明的制备方法,优选地,其包括如下步骤:According to the preparation method of the present invention, preferably, it comprises the following steps:
(1)将作为活性成分的檀香油、高良姜油、细辛油、荜茇油和冰片形成油相混合物;(1) Sandalwood oil, galangal oil, Asarum oil, Piper longum oil and Borneolum as active ingredient are formed into an oil phase mixture;
(2)将乳化剂与油相混合物混合均匀,得到第一混合物;(2) uniformly mixing the emulsifier and the oil phase mixture to obtain the first mixture;
(3)将辅料分散于水中,得到水相混合物;其中,辅料包括渗透压调节剂和/或防腐剂;(3) dispersing the auxiliary material in water to obtain an aqueous phase mixture; wherein the auxiliary material includes an osmotic pressure regulator and/or a preservative;
(4)将水相混合物与第一混合物混合,得到第二混合物;(4) mixing the aqueous phase mixture with the first mixture to obtain a second mixture;
(5)将第二混合物升温至40~60℃,然后降温至15~25℃,得到初级纳米乳液;(5) raising the temperature of the second mixture to 40-60°C, and then cooling to 15-25°C to obtain a primary nanoemulsion;
(6)用pH调节剂将初级纳米乳液的pH调节至5.5~6.5后,加水定容,得到纳米乳液。(6) After the pH of the primary nanoemulsion is adjusted to 5.5-6.5 with a pH regulator, water is added to constant volume to obtain a nanoemulsion.
在步骤(1)中,首先将檀香油、高良姜油、细辛油、荜茇油混合均匀,得到初级混合物,然后将冰片溶解在所述初级混合物中。可以采用超声溶解、搅拌或加热的方式促进冰片溶解。根据本发明的一个实施方式,将檀香油、高良姜油、细辛油、荜茇油混合均匀,得到初级混合物;搅拌条件下,将冰片溶解于初级混合物中,得到油相混合物。在纳米乳液中,初级混合物(檀香油、高良姜油、细辛油、荜茇油)的体积浓度为2~15%(v/v),更优选为5~10%(v/v)。以檀香油、高良姜油、细辛油和荜茇油的总体积为1ml计,所述冰片的用量为0.1~0.25g,优选为0.15~0.20g。In step (1), sandalwood oil, galangal oil, asarum oil, and longan oil are firstly mixed evenly to obtain a primary mixture, and then borneol is dissolved in the primary mixture. The dissolution of borneol can be promoted by means of ultrasonic dissolution, stirring or heating. According to one embodiment of the present invention, sandalwood oil, galangal oil, asarum oil, and longan oil are uniformly mixed to obtain a primary mixture; under stirring conditions, borneol is dissolved in the primary mixture to obtain an oil phase mixture. In the nanoemulsion, the volume concentration of the primary mixture (sandalwood oil, galangal oil, asarum oil, longillinium oil) is 2-15% (v/v), more preferably 5-10% (v/v). Based on 1 ml of the total volume of sandalwood oil, galangal oil, asarum oil and longan oil, the amount of borneol used is 0.1-0.25 g, preferably 0.15-0.20 g.
在步骤(2)中,将乳化剂与油相混合物混合均匀,得到第一混合物。水相混合物与第一混合物的体积比为3~15:1,优选为5~12:1,更优选为7~9:1。加料顺序并没有特别限制。例如,将乳化剂加入油相混合物中,混合均匀。在纳米乳液中,乳化剂的重量体积百分比浓度为1.2~15%(w/v),优选为1.2~9%(w/v),还优选为2~7%(w/v),更优选为3~5%(w/v)。根据本发明的一个优选实施方式,以%(w/v)计的乳化剂质量体积百分比浓度与以%(v/v)计的初级混合物体积浓度之间的比例α为0.3~0.8:1,优选为0.35~0.7:1,还优选为0.35~0.65,更优选为0.5~0.6:1。这样有助于进一步获得稳定性好的纳米乳液,提高纳米乳液的生产稳定性。In step (2), the emulsifier is uniformly mixed with the oil phase mixture to obtain a first mixture. The volume ratio of the aqueous phase mixture to the first mixture is 3-15:1, preferably 5-12:1, more preferably 7-9:1. The order of addition is not particularly limited. For example, add an emulsifier to the oil phase mixture and mix well. In the nanoemulsion, the weight volume percent concentration of the emulsifier is 1.2 to 15% (w/v), preferably 1.2 to 9% (w/v), also preferably 2 to 7% (w/v), more preferably 3 to 5% (w/v). According to a preferred embodiment of the present invention, the ratio α between the mass volume concentration of the emulsifier in % (w/v) and the volume concentration of the primary mixture in % (v/v) is 0.3 to 0.8:1, Preferably it is 0.35-0.7:1, more preferably 0.35-0.65, more preferably 0.5-0.6:1. This helps to further obtain the nanoemulsion with good stability, and improves the production stability of the nanoemulsion.
在步骤(3)中,将辅料分散于水中,得到水相混合物。辅料可以选自渗透压调节剂、防腐剂中的一种或多种。渗透压调节剂选自氯化钠、甘油、甘露醇和葡萄糖中的一种或多种。渗透压调节剂可以调节纳米乳液的渗透压比为0.8~1.3,优选为0.9~1.2,更优选为1.0~1.1。防腐剂选自苯扎氯铵、苯扎溴铵或山梨酸钾中的一种或多种,更优选为山梨酸钾。防腐剂可以抑制纳米乳液中细菌的滋生。水可以为蒸馏水、去离子水、纯水或者超纯水,优选为蒸馏水。In step (3), the auxiliary material is dispersed in water to obtain a water phase mixture. The auxiliary material can be selected from one or more of osmotic pressure regulators and preservatives. The osmotic pressure regulator is selected from one or more of sodium chloride, glycerin, mannitol and glucose. The osmotic pressure regulator can adjust the osmotic pressure ratio of the nanoemulsion to 0.8-1.3, preferably 0.9-1.2, more preferably 1.0-1.1. The preservative is selected from one or more of benzalkonium chloride, benzalkonium bromide or potassium sorbate, more preferably potassium sorbate. Preservatives can inhibit the growth of bacteria in nanoemulsions. The water may be distilled water, deionized water, pure water or ultrapure water, preferably distilled water.
在步骤(4)中,将水相混合物与第一混合物混合,得到第二混合物。混合方式并没有特别限制。例如,将水相混合物滴入第一混合物中,滴加速率并没有特别限制。In step (4), the aqueous phase mixture is mixed with the first mixture to obtain a second mixture. The mixing method is not particularly limited. For example, when the aqueous phase mixture is dropped into the first mixture, the dropping rate is not particularly limited.
在步骤(5)中,将第二混合物升温至40~60℃,优选为45~55℃,更优选为48~53℃;然后降温。可以采用冰浴快速降温。第二混合物降温至15~25℃,优选为17~23℃,更优选为19~21℃。采用相转变温度法使乳化剂的亲水亲油性质达到平衡,保证纳米乳液的稳定性。In step (5), the temperature of the second mixture is raised to 40-60° C., preferably 45-55° C., more preferably 48-53° C.; then the temperature is lowered. An ice bath can be used for rapid cooling. The temperature of the second mixture is lowered to 15-25°C, preferably 17-23°C, more preferably 19-21°C. The phase transition temperature method is used to balance the hydrophilic and lipophilic properties of the emulsifier to ensure the stability of the nanoemulsion.
在步骤(6)中,pH调节剂可以为碱金属氢氧化物的水溶液,可以选自NaOH或KOH的水溶液。配置pH调节剂所需的水可以为蒸馏水。pH调节剂的浓度为0.1~2.5mol/L,优选为0.5~2mol/L,更优选为0.8~1.2mol/L。pH调节剂将初级纳米乳液的pH调节至5.5~6.5,优选为5.7~6.3,更优选为5.9~6.1。In step (6), the pH regulator can be an aqueous solution of alkali metal hydroxide, which can be selected from aqueous solutions of NaOH or KOH. The water required for configuring the pH regulator can be distilled water. The concentration of the pH regulator is 0.1-2.5 mol/L, preferably 0.5-2 mol/L, more preferably 0.8-1.2 mol/L. The pH regulator adjusts the pH of the primary nanoemulsion to 5.5-6.5, preferably 5.7-6.3, more preferably 5.9-6.1.
本发明中,檀香油、高良姜油、细辛油和荜茇油的体积比为40~65:15~30:10~25:3~20,优选为45~60:20~28:13~20:5~15,更优选为48~55:21~25:15~18:8~12。根据本发明的一个优选实施方式,檀香油、高良姜油、细辛油和荜茇油的体积比为50:23:16:11。根据本发明的一个具体实施方式,本发明纳米乳液中包括2.5mL檀香油、1.15mL高良姜油、0.8mL细辛油和0.55mL荜茇油。In the present invention, the volume ratio of sandalwood oil, galangal oil, asarum oil and longan oil is 40~65:15~30:10~25:3~20, preferably 45~60:20~28:13~ 20:5-15, more preferably 48-55:21-25:15-18:8-12. According to a preferred embodiment of the present invention, the volume ratio of sandalwood oil, galangal oil, asarum oil and longan oil is 50:23:16:11. According to a specific embodiment of the present invention, the nanoemulsion of the present invention includes 2.5mL sandalwood oil, 1.15mL galangal oil, 0.8mL asarum oil and 0.55mL longimer oil.
根据本发明的一个实施方式,纳米乳液的制备方法包括如下步骤:According to one embodiment of the present invention, the preparation method of nanoemulsion comprises the steps:
(1)将檀香油、高良姜油、细辛油和荜茇油混合均匀,得到初级混合物,搅拌条件下,将冰片溶解于初级混合物中,得到油相混合物;(1) mixing sandalwood oil, galangal oil, asarum oil and longan oil evenly to obtain a primary mixture, and under stirring conditions, dissolving borneol in the primary mixture to obtain an oil phase mixture;
(2)将乳化剂均匀分散于油相混合物中,得到第一混合物;(2) uniformly dispersing the emulsifier in the oil phase mixture to obtain the first mixture;
(3)将辅料均匀分散于水中,得到水相混合物;辅料选自渗透压调节剂或防腐剂中的至少一种;(3) Uniformly dispersing the auxiliary material in water to obtain an aqueous phase mixture; the auxiliary material is selected from at least one of osmotic pressure regulators or preservatives;
(4)将水相混合物滴入到第一混合物中,得到第二混合物;(4) drop the aqueous phase mixture into the first mixture to obtain the second mixture;
(5)将第二混合物升温至45~55℃,降温至17~23℃,得到初级纳米乳液;(5) raising the temperature of the second mixture to 45-55° C., and cooling to 17-23° C. to obtain a primary nanoemulsion;
(6)用0.5~2mol/L的NaOH将初级纳米乳液的pH调节至5.5~6.5后,加水定容,得到所述纳米乳液。(6) After adjusting the pH of the primary nano-emulsion to 5.5-6.5 with 0.5-2 mol/L NaOH, adding water to constant volume to obtain the nano-emulsion.
根据本发明的一个具体实施方式,纳米乳液的制备方法包括如下步骤:According to a specific embodiment of the present invention, the preparation method of nanoemulsion comprises the steps:
(1)将檀香油、高良姜油、细辛油和荜茇油混合均匀,得到初级混合物,搅拌条件下,将冰片溶解于初级混合物中,得到油相混合物;(1) mixing sandalwood oil, galangal oil, asarum oil and longan oil evenly to obtain a primary mixture, and under stirring conditions, dissolving borneol in the primary mixture to obtain an oil phase mixture;
(2)将HS15均匀分散于油相混合物中,得到第一混合物;(2) Will HS15 is uniformly dispersed in the oil phase mixture to obtain the first mixture;
(3)将甘油和山梨酸钾均匀分散于蒸馏水中,得到水相混合物;(3) Glycerin and potassium sorbate are evenly dispersed in distilled water to obtain an aqueous phase mixture;
(4)将水相混合物滴入到第一混合物中,得到第二混合物;(4) drop the aqueous phase mixture into the first mixture to obtain the second mixture;
(5)将第二混合物升温至50℃,降温至20℃,得到初级纳米乳液;(5) raising the temperature of the second mixture to 50°C and cooling to 20°C to obtain the primary nanoemulsion;
(6)用1mol/L的NaOH将初级纳米乳液的pH调节至5.7~6.3后,加水定容,得到纳米乳液。(6) After adjusting the pH of the primary nanoemulsion to 5.7-6.3 with 1 mol/L NaOH, add water to constant volume to obtain a nanoemulsion.
<纳米乳液><Nanoemulsion>
本发明的纳米乳液的平均粒径小于100nm,例如为50~85nm。平均粒径的多分散指数PDI小于0.3,例如为0.05~0.2,优选为0.05~0.15。本发明的纳米乳液具有优良的稳定性能,常温保存45天,平均粒径变化幅度小于35%,优选小于10%,更优选小于5%。The average particle size of the nanoemulsion of the present invention is less than 100 nm, for example, 50-85 nm. The polydispersity index PDI of the average particle diameter is less than 0.3, for example 0.05-0.2, preferably 0.05-0.15. The nanoemulsion of the present invention has excellent stability performance, and the average particle size variation range is less than 35%, preferably less than 10%, more preferably less than 5% when stored at room temperature for 45 days.
<制剂及用途><Preparation and use>
本发明还提供一种用于治疗缺血型脑卒中的药物制剂,其含有本发明的纳米乳液,还可以包含有药学上可接受的辅料。本发明的药物制剂的剂型没有特别限制,优选为鼻用喷雾剂或鼻用凝胶剂。将纳米乳液制成鼻用喷雾剂或者加入原位凝胶制成鼻用凝胶剂,通过鼻腔给药,使药物可以绕过血脑屏障直接吸收到达中枢神经系统,降低了非靶向器官的吸收,有助于药物的定向吸收。The present invention also provides a pharmaceutical preparation for treating ischemic stroke, which contains the nanoemulsion of the present invention and may also contain pharmaceutically acceptable auxiliary materials. The dosage form of the pharmaceutical preparation of the present invention is not particularly limited, preferably nasal spray or nasal gel. Nanoemulsions are made into nasal sprays or in-situ gels are added to make nasal gels, which can be administered through the nasal cavity, so that the drugs can bypass the blood-brain barrier and directly reach the central nervous system, reducing the risk of non-targeted organs. Absorption, which contributes to the targeted absorption of drugs.
<测试方法><test method>
纳米乳液的平均粒径及多分散指数(PDI)的测试:采用激光粒度仪对纳米乳液的平均粒径及PDI进行测试。The average particle size and polydispersity index (PDI) test of the nanoemulsion: the average particle size and PDI of the nanoemulsion are tested by a laser particle size analyzer.
HS15:巴斯夫生产的非离子型表面活性剂。 HS15: Non-ionic surfactant produced by BASF.
在以下实施例和对比例中,纳米乳液中的甘油和山梨酸钾的浓度分别为2.1wt%和0.1wt%;水相混合物与第一混合物的体积比为7:1。In the following examples and comparative examples, the concentrations of glycerin and potassium sorbate in the nanoemulsion are 2.1 wt% and 0.1 wt% respectively; the volume ratio of the aqueous phase mixture to the first mixture is 7:1.
实施例1Example 1
(1)将1.5mL檀香油、0.69mL高良姜油、0.48mL细辛油和0.33mL荜茇油混合均匀,得到初级混合物,搅拌条件下,将0.48g冰片溶解于初级混合物中,得到油相混合物;(1) Mix 1.5mL sandalwood oil, 0.69mL galangal oil, 0.48mL asarum oil and 0.33mL longicorn oil to obtain a primary mixture. Under stirring conditions, dissolve 0.48g borneol in the primary mixture to obtain an oil phase mixture;
(2)将1.8gHS15均匀分散于油相混合物中,得到第一混合物;(2) Add 1.8g HS15 is uniformly dispersed in the oil phase mixture to obtain the first mixture;
(3)将甘油和山梨酸钾均匀分散于蒸馏水中,得到水相混合物;(3) Glycerin and potassium sorbate are evenly dispersed in distilled water to obtain an aqueous phase mixture;
(4)将水相混合物滴入到第一混合物中,得到第二混合物;(4) drop the aqueous phase mixture into the first mixture to obtain the second mixture;
(5)将第二混合物升温至50℃,然后降温至20℃,得到初级纳米乳液;(5) raising the temperature of the second mixture to 50°C, and then cooling to 20°C to obtain a primary nanoemulsion;
(6)用1mol/L的NaOH将所述初级纳米乳液的pH调节至6.0,加入蒸馏水定容至100mL,得到纳米乳液。所得纳米乳液的性能参见表1。(6) The pH of the primary nanoemulsion was adjusted to 6.0 with 1 mol/L NaOH, and distilled water was added to adjust the volume to 100 mL to obtain a nanoemulsion. The properties of the obtained nanoemulsion are shown in Table 1.
实施例2Example 2
(1)将2.5mL檀香油、1.15mL高良姜油、0.8mL细辛油和0.55mL荜茇油混合均匀,得到初级混合物,搅拌条件下,将0.8g冰片溶解于初级混合物中,得到油相混合物;(1) Mix 2.5mL sandalwood oil, 1.15mL galangal oil, 0.8mL asarum oil and 0.55mL longuminium oil evenly to obtain a primary mixture. Under stirring conditions, dissolve 0.8g borneol in the primary mixture to obtain an oil phase mixture;
(2)将3gHS15均匀分散于油相混合物中,得到第一混合物;(2) Add 3g HS15 is uniformly dispersed in the oil phase mixture to obtain the first mixture;
(3)将甘油和山梨酸钾均匀分散于蒸馏水中,得到水相混合物;(3) Glycerin and potassium sorbate are evenly dispersed in distilled water to obtain an aqueous phase mixture;
(4)将水相混合物滴入到第一混合物中,得到第二混合物;(4) drop the aqueous phase mixture into the first mixture to obtain the second mixture;
(5)将第二混合物升温至50℃,然后降温至20℃,得到初级纳米乳液;(5) raising the temperature of the second mixture to 50°C, and then cooling to 20°C to obtain a primary nanoemulsion;
(6)用1mol/L的NaOH将所述初级纳米乳液的pH调节至6.0,加入蒸馏水定容至100mL,得到纳米乳液。所得纳米乳液的性能参见图1、图2、表1。(6) The pH of the primary nanoemulsion was adjusted to 6.0 with 1 mol/L NaOH, and distilled water was added to adjust the volume to 100 mL to obtain a nanoemulsion. The performance of gained nanoemulsion is referring to Fig. 1, Fig. 2, table 1.
实施例3Example 3
(1)将5mL檀香油、2.3mL高良姜油、1.6mL细辛油和1.1mL荜茇油混合均匀,得到初级混合物,搅拌条件下,将1.6g冰片溶解于初级混合物中,得到油相混合物;(1) Mix 5mL sandalwood oil, 2.3mL galangal oil, 1.6mL asarum oil and 1.1mL longan oil evenly to obtain a primary mixture. Under stirring conditions, dissolve 1.6g borneol in the primary mixture to obtain an oil phase mixture ;
(2)将6gHS15均匀分散于油相混合物中,得到第一混合物;(2) Add 6g HS15 is uniformly dispersed in the oil phase mixture to obtain the first mixture;
(3)将甘油和山梨酸钾均匀分散于蒸馏水中,得到水相混合物;(3) Glycerin and potassium sorbate are evenly dispersed in distilled water to obtain an aqueous phase mixture;
(4)将水相混合物滴入到第一混合物中,得到第二混合物;(4) drop the aqueous phase mixture into the first mixture to obtain the second mixture;
(5)将第二混合物升温至50℃,然后降温至20℃,得到初级纳米乳液;(5) raising the temperature of the second mixture to 50°C, and then cooling to 20°C to obtain a primary nanoemulsion;
(6)用1mol/L的NaOH将所述初级纳米乳液的pH调节至6.0,加入蒸馏水定容至100mL,得到纳米乳液。所得纳米乳液的性能参见表1。(6) The pH of the primary nanoemulsion was adjusted to 6.0 with 1 mol/L NaOH, and distilled water was added to adjust the volume to 100 mL to obtain a nanoemulsion. The properties of the obtained nanoemulsion are shown in Table 1.
实施例4Example 4
(1)将7.5mL檀香油、3.45mL高良姜油、2.4mL细辛油和1.65mL荜茇油混合均匀,得到初级混合物,搅拌条件下,将2.4g冰片溶解于初级混合物中,得到油相混合物;(1) Mix 7.5mL sandalwood oil, 3.45mL galangal oil, 2.4mL asarum oil and 1.65mL longuminium oil to obtain a primary mixture. Under stirring conditions, dissolve 2.4g borneol in the primary mixture to obtain an oil phase mixture;
(2)将9gHS15均匀分散于油相混合物中,得到第一混合物;(2) Add 9g HS15 is uniformly dispersed in the oil phase mixture to obtain the first mixture;
(3)将甘油和山梨酸钾均匀分散于蒸馏水中,得到水相混合物;(3) Glycerin and potassium sorbate are evenly dispersed in distilled water to obtain an aqueous phase mixture;
(4)将水相混合物滴入到第一混合物中,得到第二混合物;(4) drop the aqueous phase mixture into the first mixture to obtain the second mixture;
(5)将第二混合物升温至50℃,降温至20℃,得到初级纳米乳液;(5) raising the temperature of the second mixture to 50°C and cooling to 20°C to obtain the primary nanoemulsion;
(6)用1mol/L的NaOH将所述初级纳米乳液的pH调节至6.0,加入蒸馏水定容至100mL,得到纳米乳液。所得纳米乳液的性能参见表1。(6) The pH of the primary nanoemulsion was adjusted to 6.0 with 1 mol/L NaOH, and distilled water was added to adjust the volume to 100 mL to obtain a nanoemulsion. The properties of the obtained nanoemulsion are shown in Table 1.
表1Table 1
注:α1表示以%(w/v)计的HS15质量体积百分比浓度与以%(v/v)计的初级混合物体积浓度之间的比例。Note: α1 means in % (w/v) The ratio between the mass volume percent concentration of HS15 and the primary mixture volume concentration in % (v/v).
由表1可知,当以%(w/v)计的HS15质量体积百分比浓度与以%(v/v)计的初级混合物体积浓度之间的比例α1为0.6时,改变初级混合物与乳化剂的浓度,对纳米乳液的平均粒径以及多分散指数影响不大。As can be seen from Table 1, when expressed in % (w/v) When the ratio α1 between the HS15 mass volume percent concentration and the volume concentration of the primary mixture in % (v/v) is 0.6, changing the concentration of the primary mixture and emulsifier has no effect on the average particle diameter and polydispersity index of the nanoemulsion big.
实施例5Example 5
将实施例2中的HS15用量改变为3.5g,其余条件均与实施例1相同。所得纳米乳液的性能参见图1。Will in embodiment 2 The amount of HS15 was changed to 3.5g, and all the other conditions were the same as in Example 1. The properties of the resulting nanoemulsion are shown in Figure 1.
实施例6Example 6
将实施例2中的HS15用量改变为4g,其余条件均与实施例1相同。所得纳米乳液的性能参见图1、图2。Will in embodiment 2 The amount of HS15 was changed to 4g, and all the other conditions were the same as in Example 1. The properties of the obtained nanoemulsion are shown in Fig. 1 and Fig. 2 .
实施例7Example 7
将实施例2中的HS15用量改变为4.5g,其余条件均与实施例1相同。所得纳米乳液的性能参见图1。Will in embodiment 2 The amount of HS15 was changed to 4.5g, and all the other conditions were the same as in Example 1. The properties of the resulting nanoemulsion are shown in Figure 1.
实施例8Example 8
将实施例2中的HS15用量改变为5g,其余条件均与实施例1相同。所得纳米乳液的性能参见图1、图2、表2。Will in embodiment 2 The amount of HS15 was changed to 5g, and all the other conditions were the same as in Example 1. The performance of gained nanoemulsion is referring to Fig. 1, Fig. 2, table 2.
对比例1Comparative Example 1
除将实施例5中的5gHS15替换为5g聚乙二醇1000维生素E琥珀酸酯(TPGS)以外,其余条件均与实施例5相同。所得纳米乳液的性能参见表2。Except the 5g in embodiment 5 Except that HS15 was replaced with 5 g of polyethylene glycol 1000 vitamin E succinate (TPGS), the rest of the conditions were the same as in Example 5. The performance of the obtained nanoemulsion is shown in Table 2.
对比例2Comparative Example 2
除将实施例5中的5gHS15替换为5g嵌段式聚醚F-68(Pluronic F68)以外,其余条件均与实施例5相同。所得纳米乳液的性能参见表2。Except the 5g in embodiment 5 Except that HS15 was replaced with 5 g of block polyether F-68 (Pluronic F68), the rest of the conditions were the same as in Example 5. The performance of the obtained nanoemulsion is shown in Table 2.
表2Table 2
由表2可知,与TPGS和Pluronic F68相比,采用HS15形成的纳米乳液的平均粒径小,且分布均匀。As can be seen from Table 2, compared with TPGS and Pluronic F68, using The average particle size of the nanoemulsion formed by HS15 is small and the distribution is uniform.
由图1可知,实施例1和实施例5~8中,随着纳米乳液中HS15浓度的逐渐增大,纳米乳液的平均粒径以及多分散指数均逐渐减小。As can be seen from Fig. 1, in embodiment 1 and embodiment 5~8, along with in the nanoemulsion The average particle size and polydispersity index of the nanoemulsion decreased gradually with the increasing of HS15 concentration.
由图2可知,纳米乳液中HS15的浓度为3%(w/v)相较于浓度为4%(w/v)和5%(w/v)而言,形成的纳米乳液的稳定性最好。It can be seen from Figure 2 that in the nanoemulsion The HS15 concentration of 3% (w/v) has the best stability of the formed nanoemulsion compared to the concentrations of 4% (w/v) and 5% (w/v).
本发明并不限于上述实施方式,在不背离本发明的实质内容的情况下,本领域技术人员可以想到的任何变形、改进、替换均落入本发明的范围。The present invention is not limited to the above-mentioned embodiments. Without departing from the essence of the present invention, any deformation, improvement, and replacement conceivable by those skilled in the art fall within the scope of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910452475.7A CN110075239B (en) | 2019-05-28 | 2019-05-28 | Nano emulsion and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910452475.7A CN110075239B (en) | 2019-05-28 | 2019-05-28 | Nano emulsion and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110075239A true CN110075239A (en) | 2019-08-02 |
CN110075239B CN110075239B (en) | 2021-09-03 |
Family
ID=67422123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910452475.7A Active CN110075239B (en) | 2019-05-28 | 2019-05-28 | Nano emulsion and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110075239B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112237617A (en) * | 2020-11-11 | 2021-01-19 | 杭州苏泊尔南洋药业有限公司 | Application of chest-widening composition in preparation of medicine for treating and/or preventing cerebral apoplexy |
CN116474052A (en) * | 2023-04-18 | 2023-07-25 | 中国中医科学院西苑医院 | Essential oil for scraping massage and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1732908A (en) * | 2004-08-09 | 2006-02-15 | 晏四平 | Borneol contained spray |
CN103860547A (en) * | 2014-03-26 | 2014-06-18 | 清华大学 | Antibacterial nano emulsion of Chinese herbal medicine composition and preparation method thereof |
CN110368363A (en) * | 2019-08-22 | 2019-10-25 | 北京诺康达医药科技股份有限公司 | A kind of Aprepitant fat emulsion injection and preparation method thereof |
-
2019
- 2019-05-28 CN CN201910452475.7A patent/CN110075239B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1732908A (en) * | 2004-08-09 | 2006-02-15 | 晏四平 | Borneol contained spray |
CN103860547A (en) * | 2014-03-26 | 2014-06-18 | 清华大学 | Antibacterial nano emulsion of Chinese herbal medicine composition and preparation method thereof |
CN110368363A (en) * | 2019-08-22 | 2019-10-25 | 北京诺康达医药科技股份有限公司 | A kind of Aprepitant fat emulsion injection and preparation method thereof |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112237617A (en) * | 2020-11-11 | 2021-01-19 | 杭州苏泊尔南洋药业有限公司 | Application of chest-widening composition in preparation of medicine for treating and/or preventing cerebral apoplexy |
CN117379513A (en) * | 2020-11-11 | 2024-01-12 | 浙江苏可安药业有限公司 | Breast widening composition and application thereof |
CN117379513B (en) * | 2020-11-11 | 2024-11-08 | 浙江苏可安药业有限公司 | Chest-widening composition and application thereof |
CN116474052A (en) * | 2023-04-18 | 2023-07-25 | 中国中医科学院西苑医院 | Essential oil for scraping massage and preparation method thereof |
CN116474052B (en) * | 2023-04-18 | 2024-06-07 | 中国中医科学院西苑医院 | Essential oil for scraping massage and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN110075239B (en) | 2021-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4255393B1 (en) | Topical roflumilast formulation having antifungal properties | |
CN104027299A (en) | Itraconazole temperature-sensitive type gel preparation as well as preparation method and application thereof | |
CN110075239A (en) | Nanoemulsions and its preparation method and application | |
US8603503B2 (en) | Biliquid foams stable dispersions thereof and a corresponding process of manufacturing | |
CN103501774A (en) | Semisolid aqueous pharmaceutical composition containing tapentadol | |
JP2022501314A (en) | Topical composition | |
CN103079595B (en) | Eye drip use compositions | |
WO2011103806A1 (en) | Oral microemulsion of elemene | |
CN101524325B (en) | Compound menthol microemulsion and preparation for nose | |
CN108721215B (en) | Efluconazole microemulsion composition | |
CN102166188A (en) | Oil-in-water type nanoemulsion preparation of camphor oil and preparation method thereof | |
EP3099291A1 (en) | Topical dermal compositions | |
CN101181266B (en) | Biphenyl benzyl azoles emulsion agent and preparation method thereof | |
CN101106969A (en) | O/W emulsion composition | |
EP3069712A1 (en) | Transdermal colloidal solution agent | |
CN112870161B (en) | Cedarol nanoemulsion and optimized preparation method thereof | |
WO2020070751A1 (en) | Semisolid dosage forms for ophthalmic delivery of antioxidants | |
WO2004112789A1 (en) | Ophthalmic composition | |
CN115869321A (en) | Lucotinib composition and preparation method thereof | |
MX2013012307A (en) | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents. | |
US9132295B2 (en) | Composition having stabilized perfluorocarbons | |
WO2021032073A1 (en) | In-situ gel containing cyclosporine micelles as sustained ophthalmic drug delivery system | |
EP3124049A1 (en) | Process for producing composition of emulsion preparation type | |
EP4201401A1 (en) | Ophthalmic microemulsion, procedure for obtaining and use thereof | |
EP4288030B1 (en) | An aqueous gel composition comprising an ethylcellulose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 110016 No. 103, Wenhua Road, Shenhe District, Liaoning, Shenyang Patentee after: SHENYANG PHARMACEUTICAL University Patentee after: Zhejiang sukean Pharmaceutical Co., Ltd Address before: 110016 No. 103, Wenhua Road, Shenhe District, Liaoning, Shenyang Patentee before: SHENYANG PHARMACEUTICAL University Patentee before: Hangzhou SUPOR Nanyang Pharmaceutical Co., Ltd |
|
CP01 | Change in the name or title of a patent holder |